CSL LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 276.3 AUD | -1.28% |
|
+0.36% | -3.58% |
| 03:14am | Australian shares retreat as miners, banks drag; CBA down on lower profit | RE |
| 07/05 | Australia's CSL tests 'dynamic pricing' of donor blood amid cost surge | RE |
Presenter SpeechJohn Shine (Executives)Okay. We might get started. Welcome very much, ladies a...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
CSL Limited is an Australia-based biotechnology company. The Companyâs areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Companyâs segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.
Sector
Pharmaceuticals
Calendar
13/08/2024
- Q4 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
184
USD
Average target price
199.6
USD
Spread / Average Target
+8.50%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.58% | 89.33B | |
| +4.08% | 41.19B | |
| -15.09% | 31.87B | |
| +53.68% | 24.52B | |
| -15.13% | 15.68B | |
| -8.63% | 12.34B | |
| -40.39% | 12.23B | |
| +6.22% | 8.83B | |
| -5.85% | 8.28B | |
| -6.45% | 7.52B |
- Stock Market
- Equities
- CSL Stock
- News CSL Limited
- Transcript : CSL Limited - Shareholder/Analyst Call